Alzamend Neuro Inc. (ALZN)
NASDAQ: ALZN
· Real-Time Price · USD
0.64
-0.04 (-5.88%)
At close: May 06, 2025, 3:59 PM
0.66
3.94%
Pre-market: May 07, 2025, 08:48 AM EDT
-5.88% (1D)
| Bid | 0.65 |
| Market Cap | 4.2M |
| Revenue (ttm) | 76.11K |
| Net Income (ttm) | -4.23M |
| EPS (ttm) | -134.51 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.52 |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 111,741 |
| Avg. Volume (20D) | 395,301 |
| Open | 0.70 |
| Previous Close | 0.68 |
| Day's Range | 0.63 - 0.70 |
| 52-Week Range | 0.63 - 15.06 |
| Beta | -0.17 |
About ALZN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALZN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+5.03%
Alzamend Neuro shares are trading higher after the...
Unlock content with
Pro Subscription
8 months ago
+186.76%
Alzamend Neuro shares are trading higher after the company announced that it is partnering with Massachusetts General Hospital as its contract research organization to conduct first of its kind Phase II clinical study of AL001 for treatment of patients with PTSD.
